MAB-CHMINACA

131.70491.70

Clear
SKU: MAB-CHMINACA Category:

ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015.

Legal status

In the United States, ADB-CHMINACA is a Schedule I controlled substance. Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014.[13] Sweden’s public health agency suggested to classify

ADB-CHMINACA as hazardous substance on November 10, 2014. ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.

ADB-CHMINACA is illegal in Switzerland as of December 2015.

IUPAC name

N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide

CAS Number

1185887-13-1

Formula

C21H30N4O2

Molar mass

370.497 g·mol−1

Reviews

There are no reviews yet.

Be the first to review “MAB-CHMINACA”

Your email address will not be published. Required fields are marked *